Assessing the relationship between systemic immune-inflammation index and mortality in patients with hypertrophic cardiomyopathy.

Ziqiong Wang,Xiaoping Chen,Ye Zhu,Jiafu Wei,Xin Wei,Liying Li,Sen He,Haiyan Ruan

doi:10.48101/ujms.v126.8124

Abstract

BackgroundThis study investigates the predictive value of the systemic immune-inflammation index (SII), which was calculated as platelet × neutrophil/lymphocyte ratio, for all-cause mortality in patients with hypertrophic cardiomyopathy (HCM).MethodsA total of 360 HCM patients were enrolled. They were divided into three groups based on the tertiles of baseline SII. The association between SII and all-cause mortality was analyzed.ResultsThere were 53 HCM patients who died during a mean follow-up time of 4.8 years (min: 6 days and max: 10.8 years), and the mortality rate was 3.0 per 100 person years. The cumulative mortality rate was significantly different among the three tertiles of SII (P = 0.004), and the mortality rate in tertile 3 was much higher than that in the first two tertiles. In reference to tertile 1, the fully adjusted hazard ratios of all-cause mortality were 1.02 for the tertile 2 (95% confidence interval [CI]: 0.45–2.31, P = 0.966) and 2.31 for tertile 3 (95% CI: 1.10–4.87, P = 0.027). No significant interactions between SII and other variables were observed during subgroup analysis. The discriminative power was better for mid-term outcome than that for short-term or long-term outcomes. Sensitivity analyses including patients with normal platelet and white blood cell count have revealed similar results.ConclusionSII was a significant risk factor for all-cause mortality in HCM patients. However, the discriminative power was poor to moderate. It could be used in combination with other risk factors in mortality risk stratification in HCM.

Highlights

Hypertrophic cardiomyopathy (HCM) is the most frequent genetically transmitted heart disease with an estimated prevalence of 1:500 to 1:200 [1]
Several studies indicated that markers of inflammation predicted adverse outcomes in hypertrophic cardiomyopathy (HCM), such as high-sensitivity C reactive protein (CRP) [7], monocyte to high density lipoprotein cholesterol ratio (M/HDL-C) [8], and neutrophil to lymphocyte ratio (NLR) [10]
In the present cohort study of HCM, we firstly proved its predictive value for all-cause mortality, which consisted of sudden cardiac death (SCD), heart failure (HF)-related death, stroke-related death, cancer-related death, etc

Summary

Introduction

Hypertrophic cardiomyopathy (HCM) is the most frequent genetically transmitted heart disease with an estimated prevalence of 1:500 to 1:200 [1]. Several studies indicated that markers of inflammation predicted adverse outcomes in HCM, such as high-sensitivity C reactive protein (CRP) [7], monocyte to high density lipoprotein cholesterol ratio (M/HDL-C) [8], and neutrophil to lymphocyte ratio (NLR) [10]. A novel immune and inflammation index, namely, systemic immune-inflammation index (SII), which is calculated from platelet, neutrophil, and lymphocyte counts, has been examined as a prognostic factor for clinical outcomes in cancer patients [11,12] and in patients with cardiovascular diseases, such as coronary artery disease [13,14], hypertension [15], pulmonary embolism [16], and acute ischemic stroke [17]. The present study investigated the prognostic value of SII for mortality in HCM patients from a tertiary referral center

Methods

Results

Discussion

Conclusion

Notes on contributors